Care Access Research

1. AstraZeneca Pharmaceuticals LP $1,877,527 76 payments
2. Celgene Corporation $1,301,172 28 payments
3. Novartis Pharmaceuticals Corporation $672,123 34 payments
4. GlaxoSmithKline, LLC. $397,131 73 payments
5. AstraZeneca UK Limited $94,016 3 payments
6. AbbVie, Inc. $84,881 40 payments
7. E.R. Squibb & Sons, L.L.C. $84,488 8 payments
8. Ironwood Pharmaceuticals, Inc $39,226 30 payments
9. Novo Nordisk AS $27,646 163 payments
10. Ucb SA $18,754 9 payments

1. A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS $854,739 20 payments
2. Phase III CC-93538 Treat-Through (CC-93538-EE-001) Wk24 PE Primary - A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolesc $615,480 11 payments
3. A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma $328,784 13 payments
4. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $301,286 6 payments
5. Phase III Study - Long Term Extension/Rollover from EE-001 - A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagiti $256,923 6 payments
6. A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Dose Find $149,133 18 payments
7. A Multi-Center, Multi-National, Randomized, Double - A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects wit $137,015 2 payments
8. A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non cirrhotic Non alcoholic Steatohepatitis with Fibrosis $133,734 6 payments
9. A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event $120,103 6 payments
10. A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. $116,446 5 payments

1. Other $11,810 10 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.